- Volume 13 Issue 8
DOI QR Code
Retrospective Analysis of 498 Primary Soft Tissue Sarcomas in a Single Turkish Centre
- Duman, Berna Bozkurt ;
- Gunaldi, Meral ;
- Ercolak, Vehbi ;
- Afsar, Cigdem Usul ;
- Sahin, Berksoy ;
- Erkisi, I. Melek Koksal ;
- Kara, Oguz ;
- Paydas, Semra ;
- Gonlusen, Gulfiliz ;
- Sertdemir, Yasar
- Published : 2012.08.31
Background: Soft tissue sarcomas (STS) must be managed with a team involving pathologists, radiologists, surgeons, radiation therapists and medical oncologists. Treatment modalities and demographic charasteristics of Turkish STS were analysed in the current study. Material-Methods: Primary adult STS followed between 1999-2010 in Cukurova University Medical Faculty Department of Medical Oncology were analzied retrospectively Results: Of the total of 498 patients, 238 were male and 260 female. The most seen adult sarcomas were leomyosarcoma (23%). Localization of disease was upper extremity (8.8%), lower extremity (24.7%), head-neck 8.2%, thoracic 8%, retroperitoneal 5.6%, uterine 12.4%, abdominal 10%, pelvic region 3.6 and other regions 10%. Some 13.1% were early stage, 10.2% locally advanced, 8.2% metastatic and 12.2% recurrent disease. Patients were treated with neoadjuvant/adjuvant (12%) or palliative chemotherapy (7.2%) and 11.4% patients did not receive chemotherapy. Surgery was performed as radical or conservative. The most preferred regimen was MAID combination chemotherapy in the rate of 17.6%. The most common metastatic site was lung (18.1%). The overall survival was 45 months (95%CI 30-59), 36 months in men and 55 months in women, with no statistically significant difference (p=0.5). The survival rates were not different between the group of adjuvant and palliative chemotherapy (respectively 28 versus 18 months) (p=0.06), but radical surgery at 37 months was better than 22 months for conservative surgery (p=0.0001). No differences were evident for localization (p=0.152). Locally advanced group had higher overall survival rates (72 months) than other stages (p=0.0001). Conclusion: STS can be treated successfully with surgery, chemotherapy and radiotherapy. The survival rates of Turkish people were higher in locally advanced group; these results show the importance of multimodality treatment approach and radical surgery.
Soft tissue sarcoma;surgery;chemotherapy;radiotherapy;Turkey
- Alkis N, Muallaoğlu S, Koçer M, et al (2011). Primary adult soft tissue sarcomas: analysis of 294 patients. Med Oncol, 28, 391-6. https://doi.org/10.1007/s12032-010-9450-2
- Baratti D, Pennacchioli E, Casali PG, et al (2007). Epithelioid sarcoma: prognostic factors and survival in a series of patients treated at a single institution. Ann Surg Oncol, 14, 3542. https://doi.org/10.1245/s10434-007-9628-9
- Bissler JJ, McCormack FX, Young LR, et al (2008). Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med, 358, 140-51. https://doi.org/10.1056/NEJMoa063564
- Bramwell VH, Anderson D, Charette ML (2003). Sarcoma disease site group. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database Syst Rev, 3, 3293.
- Butrynski JE, D'Adamo DR, Hornick JL, et al (2010). Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med, 363, 1727-33. https://doi.org/10.1056/NEJMoa1007056
- Cesne AL, Cresta S, Maki RG, et al (2012). A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas. Eur J Cancer, ?, ?-?.
- Coindre JM, Terrier P, Guillou L, et al (2001). Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer, 91, 1914-26. https://doi.org/10.1002/1097-0142(20010515)91:10<1914::AID-CNCR1214>3.0.CO;2-3
- Cormier JN, Pollock RE (2004). Soft tissue sarcomas. CA Cancer J Clin, 54, 94-109. https://doi.org/10.3322/canjclin.54.2.94
- Clasby R, Tilling K, Simith MA, Fletcher CD (1997). Varaible management of soft tissue sarcoma regional audit with implication for specialist care. Br J Surg, 84, 1692-6. https://doi.org/10.1002/bjs.1800841213
- DeLaney TF, Trofimov AV, Engelsman M, Suit HD (2005). Advanced-technology radiation therapy in the management of bone and soft tissue sarcomas. Cancer Control, 12, 27-35. https://doi.org/10.1177/107327480501200104
- Ducimetière F, Lurkin A, Ranchère-Vince D, et al (2011). Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLoS One, 6, 20294. https://doi.org/10.1371/journal.pone.0020294
- Fletcher CDM, Unni KK, Mertens F (2002). World Health Organization Classification of tumours: Pathology and Genetics of tumours of soft tissue and bone, IARC Press, Lyon 2002.
- Hensley ML, Maki R, Venkatraman E, et al (2002).Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol, 20, 2824-31. https://doi.org/10.1200/JCO.2002.11.050
- Lawrence W Jr, Donegan WL, Natarajan N, et al (1987). Adult soft tissue sarcomas. A pattern of care survey of the American college of surgeons. Ann Surg, 205, 349. https://doi.org/10.1097/00000658-198704000-00003
- Maki RG, Wathen JK, Patel SR, et al (2007). Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol, 25, 2755-63. https://doi.org/10.1200/JCO.2006.10.4117
- Maki RG, D'Adamo DR, Keohan ML, et al (2009). Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol, 27, 3133-40. https://doi.org/10.1200/JCO.2008.20.4495
- Pervaiz N, Colterjohn N, Farrokhyar F, et al (2008). A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer, 113, 573. https://doi.org/10.1002/cncr.23592
- Sakharpe A, Lahat G, Gulamhusein T, et al (2011). Epithelioid sarcoma and unclassified sarcoma with epithelioid features: clinicopathological variables, molecular markers, and a new experimental model. Oncologist, 16, 512. https://doi.org/10.1634/theoncologist.2010-0174
- Siegel R, Naishadham D, Jemal A (2012). Cancer statistics. CA Cancer J Clin, 62, 10 https://doi.org/10.3322/caac.20138
- Sleijfer S, Ray-Coquard I, Papai Z, et al (2009). Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol, 27, 3126-32. https://doi.org/10.1200/JCO.2008.21.3223
- Stacchiotti S, Longhi A, Ferraresi V, et al (2012). Phase II study of imatinib in advanced chordoma. J Clin Oncol, 30, 914-20. https://doi.org/10.1200/JCO.2011.35.3656
- Stacchiotti S, Negri T, Libertini M, et al (2012). Sunitinib malate in solitary fibrous tumor (SFT). Ann Oncol, ?, ?-?.
- Computed Tomography Manifestations of Histologic Subtypes of Retroperitoneal Liposarcoma vol.15, pp.15, 2014, https://doi.org/10.7314/APJCP.2014.15.15.6041
- Adult Urological Soft Tissue Sarcomas: A Multicenter Study of the Anatolian Society of Medical Oncology (ASMO) vol.16, pp.11, 2015, https://doi.org/10.7314/APJCP.2015.16.11.4777
- Clinicopathologic characteristics, treatment outcomes, and prognostic factors of primary thoracic soft tissue sarcoma: A multicenter study of the Anatolian Society of Medical Oncology (ASMO) vol.6, pp.1, 2015, https://doi.org/10.1111/1759-7714.12150